The busi­ness mod­el of End­points News — and why you should sub­scribe

Pisa, Italy – 2008
From the pub­lish­er

Our busi­ness mod­el is ex­pand­ing to­day. In short: you can keep read­ing us for free, but we’re adding new ben­e­fits with paid sub­scrip­tions, and not tak­ing any con­tent away. We re­main com­mit­ted to ac­ces­si­ble jour­nal­ism.  But we plan on grow­ing the group at End­points, and we’d like your sup­port for that. So we’re ask­ing read­ers — both com­pa­nies and in­di­vid­u­als — to pur­chase one of two new sub­scrip­tion prod­ucts.

Up­grade my sub­scrip­tion now

In­di­vid­u­als

In­sid­er $200/yr

Ben­e­fits No email ads, print to PDF, ex­clu­sive opin­ion con­tent, sup­port our growth and be amongst the ear­li­est adopters of our in­de­pen­dent jour­nal­ism mod­el.

Com­pa­nies (all sizes)

En­ter­prise $1,000/yr

Li­cense Un­lim­it­ed cut-and-paste and reprint rights; pri­vate news­feed for com­pa­ny re­broad­cast, print to PDF, and ex­clu­sive opin­ion con­tent. The best way a com­pa­ny can sup­port End­points News. One li­cense cov­ers every em­ploy­ee no mat­ter how large or small the firm.


For over a year now, co-founder John Car­roll and I have been build­ing a busi­ness news com­pa­ny on an open mod­el be­cause we be­lieve the news ought to be free, ac­ces­si­ble, and eas­i­ly dis­cov­er­able by the right au­di­ences. Our job is to cre­ate a news­feed which bio­phar­ma read­ers seek out and will­ing­ly re­turn to.

We think 60% of you will not, un­der any cir­cum­stance, pay for con­tent. And that’s no prob­lem. We wel­come you, and noth­ing much will change.

Free sub­scribers will con­tin­ue get­ting full-fi­deli­ty Ear­ly Edi­tion and Fea­ture Edi­tion dai­ly email newslet­ters, plus up to four spon­sored emails per month, and en­joy one-click reg­is­tra­tion ac­cess to spe­cial re­ports and deep dives. This is all sup­port­ed by email mar­ket­ing cam­paigns from spon­sors who part­ner with us di­rect­ly to show you rel­e­vant cam­paigns.

For com­pa­nies and in­di­vid­u­als who want to sup­port our work, or could use the new ben­e­fits we’re in­tro­duc­ing to­day, the In­sid­er and En­ter­prise plans are for you.

Do I/we need a sub­scrip­tion? 

(1) Do you cut-and-paste lib­er­al­ly, be­yond fair use, from our web­site and share con­tent with col­leagues or with clients?

(2) Do you for­ward our emails or ar­ti­cles to a com­pa­ny-wide dis­tri­b­u­tion?

If the an­swer is yes to ei­ther, you need an En­ter­prise Plan li­cense.

The plan is made for near­ly all busi­ness pur­pos­es and in­tents. If you work in PR, me­dia mon­i­tor­ing, or ad­ver­tis­ing, and we re­port on your clients, chances are you might want to legal­ly use our con­tent to present it in your own for­mat or medi­um. This plan is for you.

If we buy an En­ter­prise Plan, does that mean every­one in my com­pa­ny is cov­ered?

Yes. Every­one in your com­pa­ny is cov­ered if just one per­son is the hold­er of a cur­rent En­ter­prise sub­scrip­tion. If you work at Mer­ck or Lemon­ade Stand Biotech, the price is the same.

Does the En­ter­prise plan in­clude every­thing the In­sid­er has?

No. The In­sid­er plan in­cludes the ad-free ex­pe­ri­ence. En­ter­prise plans on­ly in­clude it for the ac­count hold­er, but that ben­e­fit does not ex­tend to the en­tire com­pa­ny.

Why are you do­ing sub­scrip­tions? Isn’t the spon­sored con­tent busi­ness de­cent?

Top-class brands like Catal­ent, PPD, Brack­et, in­Ven­tiv Health Con­sult­ing, and more, all got on the ground floor and part­nered with us on smart, high-im­pact cam­paigns for their brands in our first year. You will be see­ing a lot more of that in the years to come be­cause it’s a cru­cial piece of our fu­ture.

Ar­salan Arif

But the truth is, no­body can tell the fu­ture of the news busi­ness, so like any good en­ter­prise, we’re di­ver­si­fy­ing our rev­enue. And for us, there can be no bet­ter rev­enue than the kind we get di­rect­ly from our au­di­ence. Our goal is to be around for a while. Noth­ing is more im­por­tant to our fu­ture than this pro­gram.

We have a few non-ne­go­tiables. Sharp writ­ing, con­sis­ten­cy, an­swer­able on­ly to read­ers, re­li­ably de­liv­ered, pre­sent­ed clean­ly — with full fi­deli­ty in email and on the web. No tech­ni­cal lim­i­ta­tions placed on read­ers. These are our prin­ci­ples.

And all of those ideals cost re­al mon­ey. We’re aware of the mar­gin­al cost of cre­at­ing con­tent on­line to­day. It’s painful­ly and ab­solute­ly ze­ro. But we think good con­tent and ideas will win, but not with­out the di­rect sup­port of our read­ers.

We’re go­ing to keep work­ing for it every day. We hope you join us.

Up­grade my sub­scrip­tion now

The top 10 block­buster drugs in the late-stage pipeline — Eval­u­ate adds 6 new ther­a­pies to heavy-hit­ter list

Vertex comes in for a substantial amount of criticism for its no-holds-barred tactical approach toward wresting the price it wants for its commercial drugs in Europe. But the flip side of that coin is a highly admired R&D and commercial operation that regularly wins kudos from analysts for their ability to engineer greater cash flow from the breakthrough drugs they create.

Both aspects needed for success in this business are on display in the program backing Vertex’s triple for cystic fibrosis. VX-659/VX-445 + Tezacaftor + Ivacaftor — it’s been whittled down to 445 now — was singled out by Evaluate Pharma as the late-stage therapy most likely to win the crown for drug sales in 5 years, with a projected peak revenue forecast of $4.3 billion.

The latest annual list, which you can see here in their latest world preview, includes a roster of some of the most closely watched development programs in biopharma. And Evaluate has added 6 must-watch experimental drugs to the top 10 as drugs fail or go on to a first approval. With apologies to the list maker, I revamped this to rank the top 10 by projected 2024 sales, instead of Evaluate's net present value rankings.

It's how we roll at Endpoints News.

Here is a quick summary of the rest of the top 10:

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.

How small- to mid-sized biotechs can adopt pa­tient cen­tric­i­ty in their on­col­o­gy tri­als

By Lucy Clos­sick Thom­son, Se­nior Di­rec­tor of On­col­o­gy Pro­ject Man­age­ment, Icon

Clin­i­cal tri­als in on­col­o­gy can be cost­ly and chal­leng­ing to man­age. One fac­tor that could re­duce costs and re­duce bar­ri­ers is har­ness­ing the pa­tient voice in tri­al de­sign to help ac­cel­er­ate pa­tient en­roll­ment. Now is the time to adopt pa­tient-cen­tric strate­gies that not on­ly fo­cus on pa­tient needs, but al­so can main­tain cost ef­fi­cien­cy.

John Reed at JPM 2019. Jeff Rumans for Endpoints News

Sanofi's John Reed con­tin­ues to re­or­ga­nize R&D, cut­ting 466 jobs while boost­ing can­cer, gene ther­a­py re­search

The R&D reorganization inside Sanofi is continuing, more than a year after the pharma giant brought in John Reed to head the research arm of the Paris-based company.
Endpoints News

Basic subscription required

Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.

John Chiminski, Catalent CEO - File Photo

'It's a growth play': Catal­ent ac­quires Bris­tol-My­er­s' Eu­ro­pean launch pad, ex­pand­ing glob­al CD­MO ops

Catalent is staying on the growth track.

Just two months after committing $1.2 billion to pick up Paragon and take a deep dive into the sizzling hot gene therapy manufacturing sector, the CDMO is bouncing right back with a deal to buy out Bristol-Myers’ central launchpad for new therapies in Europe, acquiring a complex in Anagni, Italy, southwest of Rome, that will significantly expand its capacity on the continent.

There are no terms being offered, but this is no small deal. The Anagni campus employs some 700 staffers, and Catalent is planning to go right in — once the deal closes late this year — with a blueprint to build up the operations further as they expand on oral solid, biologics, and sterile product manufacturing and packaging.

This is an uncommon deal, Catalent CEO John Chiminski tells me. But it offers a shortcut for rapid growth that cuts years out of developing a green fields project. That’s time Catalent doesn’t have as the industry undergoes unprecedented expansion around the world.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.

Arc­turus ex­pands col­lab­o­ra­tion, adding $30M cash; Ku­ra shoots for $100M raise

→  Rare dis­ease play­er Ul­tragenyx $RARE is ex­pand­ing its al­liance with Arc­turus $ARCT, pay­ing $24 mil­lion for eq­ui­ty and an­oth­er $6 mil­lion in an up­front as the two part­ners ex­pand their col­lab­o­ra­tion to in­clude up to 12 tar­gets. “This ex­pand­ed col­lab­o­ra­tion fur­ther so­lid­i­fies our mR­NA plat­form by adding ad­di­tion­al tar­gets and ex­pand­ing our abil­i­ty to po­ten­tial­ly treat more dis­eases,” said Emil Kakkis, the CEO at Ul­tragenyx. “We are pleased with the progress of our on­go­ing col­lab­o­ra­tion. Our most ad­vanced mR­NA pro­gram, UX053 for the treat­ment of Glyco­gen Stor­age Dis­ease Type III, is ex­pect­ed to move in­to the clin­ic next year, and we look for­ward to fur­ther build­ing up­on the ini­tial suc­cess of this part­ner­ship.”

UP­DAT­ED: Chica­go biotech ar­gues blue­bird, Third Rock 'killed' its ri­val, pi­o­neer­ing tha­lassemia gene ther­a­py in law­suit

Blue­bird bio $BLUE chief Nick Leschly court­ed con­tro­ver­sy last week when he re­vealed the com­pa­ny’s be­ta tha­lassemia treat­ment will car­ry a jaw-drop­ping $1.8 mil­lion price tag over a 5-year pe­ri­od in Eu­rope — mak­ing it the plan­et’s sec­ond most ex­pen­sive ther­a­py be­hind No­var­tis’ $NVS fresh­ly ap­proved spinal mus­cu­lar at­ro­phy ther­a­py, Zol­gens­ma, at $2.1 mil­lion. A Chica­go biotech, mean­while, has been fum­ing at the side­lines. In a law­suit filed ear­li­er this month, Er­rant Gene Ther­a­peu­tics al­leged that blue­bird and ven­ture cap­i­tal group Third Rock un­law­ful­ly prised a vi­ral vec­tor, de­vel­oped in part­ner­ship with the Memo­r­i­al Sloan Ket­ter­ing Can­cer Cen­ter (MSK), from its grasp, and thwart­ed the de­vel­op­ment of its sem­i­nal gene ther­a­py.

Neil Woodford. Woodford Investment Management via YouTube

Wood­ford braces po­lit­i­cal storm as UK fi­nan­cial reg­u­la­tors scru­ti­nize fund sus­pen­sion

The shock of Neil Wood­ford’s de­ci­sion to block with­drawals for his flag­ship fund is still rip­pling through the rest of his port­fo­lio — and be­yond. Un­der po­lit­i­cal pres­sure, UK fi­nan­cial reg­u­la­tors are now tak­ing a hard look while in­vestors con­tin­ue to flee.

In a re­sponse let­ter to an MP, the Fi­nan­cial Con­duct Au­thor­i­ty re­vealed that it’s opened an in­ves­ti­ga­tion in­to the sus­pen­sion fol­low­ing months of en­gage­ment with Link Fund So­lu­tions, which tech­ni­cal­ly del­e­gat­ed Wood­ford’s firm to man­age its funds.

Gilead baits new al­liance with $45M up­front, div­ing in­to the busy pro­tein degra­da­tion field

Gilead is jump­ing on board the pro­tein degra­da­tion band­wag­on. And they’re turn­ing to a low-pro­file Third Rock start­up for the ex­per­tise. But if you were look­ing for a trans­for­ma­tion­al deal to kick up fresh en­thu­si­asm for Gilead, you’ll have to re­main pa­tient.

This one will have a long way to go be­fore they get in­to the clin­ic.

The big biotech said Wednes­day morn­ing that it is pay­ing $45 mil­lion up­front and re­serv­ing a whop­ping $2.3 bil­lion in biotech bucks if San Fran­cis­co-based Nurix can point the way to new can­cer ther­a­pies, as well as drugs for oth­er, un­spec­i­fied dis­eases.

A new num­ber 1 drug? Keytru­da tapped to top the 10 biggest block­busters on the world stage by 2024

Analysts may be fretting about Keytruda’s longterm prospects as a host of rival therapies elbow their way to the market. But the folks at Evaluate Pharma are confident that last year’s $7 billion earner is headed for glory, tapping it to beat out the current #1 therapy Humira as AbbVie watches that franchise swoon over the next 5 years.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.